BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Cash Flow-to-Debt Ratio
BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Cash Flow-to-Debt Ratio of 0.48x as of June 2024, meaning its operating cash flow of €8.36 Billion could theoretically repay 0% of its total liabilities (€17.44 Billion) in one year. See BEXIMCO PHARMA.GDR REGS 1 (R2WA) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BEXIMCO PHARMA.GDR REGS 1 Cash Flow-to-Debt Ratio (2022–2024)
Historical debt coverage capacity for BEXIMCO PHARMA.GDR REGS 1 across 3 annual periods. For the full cash flow conversion analysis, see how efficiently does BEXIMCO PHARMA.GDR REGS 1 generate cash.
Annual Cash Flow-to-Debt Ratio for BEXIMCO PHARMA.GDR REGS 1 (2022–2024)
Year-by-year debt coverage analysis for BEXIMCO PHARMA.GDR REGS 1. Check BEXIMCO PHARMA.GDR REGS 1 (R2WA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.48x | €8.36 Billion | €17.44 Billion | ▲ +69.7% |
| 2023 | 0.28x | €6.08 Billion | €21.54 Billion | ▲ +16.6% |
| 2022 | 0.24x | €5.21 Billion | €21.51 Billion | — |